NEO · XBRL financial data

Neogenomics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (NEO's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cost of goods and services sold	88*	91	92	93	95*	95	104	107	107*	106	110	113
Gross profit	—	65	72	75	—	73	77	80	—	81	92	97
Research and development	7*	8	8	8	8*	10	9	9	9*	10	11	10
General and administrative	60*	66	63	67	64*	68	72	70	64*	66	64	67
Total operating expenses	86*	96	94	96	96*	101	125	107	97*	99	102	105
Operating income (loss)	(19)*	(31)	(22)	(21)	(18)*	(28)	(48)	(27)	(13)*	(18)	(10)	(8)
Interest income	5*	5	5	5	4*	4	2	2	2*	1	1	1
Interest expense	14*	2	2	2	2*	2	1	1	1*	1	1	1
Other income (expense)	0*	(0)	(0)	0	(0)*	0	0	(0)	0*	(0)	(0)	(0)
Income tax expense (benefit)	(1)*	(1)	(0)	(0)	(1)*	0	(1)	1	(3)*	(0)	(0)	(0)
Net income (loss)	(14)*	(27)	(19)	(18)	(15)*	(26)	(45)	(27)	(10)*	(17)	2	(8)
Weighted average shares, basic millions of shares	126*	126	126	127	127*	127	128	128	129*	129	130	129
Weighted average shares, diluted millions of shares	126*	126	126	127	127*	127	128	128	129*	129	131	129

Fiscal quarters (NEO's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	342	332	355	362	367	346	155	164	160	146	146	139
Accounts receivable	131	140	147	151	151	151	153	155	159	167	175	213
Inventory	24	20	23	24	27	30	34	28	29	30	27	26
Total current assets	597	574	584	590	596	574	393	382	376	374	381	410
Property and equipment, net	92	88	92	93	94	90	85	85	85	84	81	86
Right-of-use asset	92	87	84	81	80	78	83	80	78	77	79	78
Goodwill	523	523	523	523	523	523	524	524	524	524	524	524
Total assets	1,681	1,640	1,643	1,641	1,638	1,601	1,394	1,375	1,360	1,347	1,352	1,377
Accounts payable	20	18	17	17	22	16	27	23	23	26	21	33
Current portion of long-term debt	—	—	—	—	201	—	—	—	0	—	—	—
Total current liabilities	96	77	290	296	301	280	100	98	88	85	106	116
Long-term debt	538	—	—	—	340	—	—	—	342	—	374	375
Lease liability, non-current	68	65	63	62	61	60	67	64	63	61	65	64
Total liabilities	740	717	727	733	736	713	540	536	523	518	567	576
Accumulated deficit	(247)	(274)	(293)	(310)	(326)	(352)	(397)	(424)	(434)	(451)	(449)	(456)
Total stockholders' equity	942	923	916	908	902	888	854	838	837	829	786	801
Total liabilities and equity	1,681	1,640	1,643	1,641	1,638	1,601	1,394	1,375	1,360	1,347	1,352	1,377
Common shares outstanding (cover page) millions of shares	128	128	128	128	128	129	129	129	130	130	128	129

Fiscal quarters (NEO's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(14)*	(27)	(19)	(18)	(15)*	(26)	(45)	(27)	(10)*	(17)	2	(8)
Stock-based compensation	7*	8	9*	0	8*	11	12*	10*	8*	10	8*	9*
Net cash from operating activities	18*	(26)	14*	9*	10*	(25)	20*	9*	1*	(8)	20*	(9)*
Purchases of property and equipment	7*	6	13*	11*	12*	5	6*	8*	8*	5	8*	12*
Net cash from investing activities	17*	15	7*	(4)*	(5)*	4	(9)*	(0)*	(6)*	(5)	(8)*	(12)*
Proceeds from issuing common stock	1*	1	2*	1*	1*	1	(1)*	1*	0*	(0)	2*	1*
Share repurchases	—	—	—	—	—	—	—	0*	—	—	—	0*
Net cash from financing activities	1*	1	2*	1*	1*	1	(202)*	1*	0*	(0)	(12)*	14*
Net change in cash	—	(11)	23*	7*	—	—	—	9*	—	—	—	(6)*

SIC 8734 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8734 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Neogenomics	139	209	(8.9)*	129.4M	18.9 quarters	Q3 FY26 10-QSep 30, 2026
Absci	108	not reported	(28)*	171.6M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
Maxcyte	15	7.3	(4.7)*	103.2M	22.7 quarters	Q2 FY26 10-QJun 30, 2026
NRC Health	3.3	35	1.4*	22.1M	—	Q2 FY26 10-QJun 30, 2026
OmniAb	23	4	11*	145.9M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.